title: Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis.
abstract: OBJECTIVE
  SPD476 (MMX mesalamine), a novel, once-daily mesalamine formulation, uses MMX Multi Matrix System (MMX) technology to delay and extend delivery of active drug throughout the colon. We performed a randomized, double-blind, parallel-group, placebo-controlled, multicenter phase III study in patients with mild to moderately active ulcerative colitis.
  
  
  METHODS
  Two hundred eighty patients with mild to moderately active ulcerative colitis received MMX mesalamine 2.4 g/day given twice daily (n = 93), 4.8 g/day given once daily (n = 94), or placebo (n = 93) for 8 weeks. The primary end point was the percentage of patients in clinical and endoscopic remission (modified ulcerative colitis disease activity index score of < or =1, with a score of 0 for rectal bleeding and stool frequency, and at least a 1-point reduction in sigmoidoscopy score) at week 8. Patients with mucosal friability were not considered to have achieved this end point.
  
  
  RESULTS
  Clinical and endoscopic remission at week 8 was achieved by 34.1% and 29.2% of patients receiving MMX mesalamine 2.4 g/day given twice daily and MMX mesalamine 4.8 g/day given once daily, respectively, versus 12.9% receiving placebo (P < .01). MMX mesalamine was generally well-tolerated.
  
  
  CONCLUSIONS
  MMX mesalamine given once or twice daily is well-tolerated and, compared with placebo, demonstrated efficacy for the induction of clinical and endoscopic remission in mild to moderately active ulcerative colitis.
authors.affiliation: Division of Gastroenterology, University of Pennsylvania, Philadelphia, Pennsylvania 19104-4283, USA.
authors.forename: Gary R
authors.initials: GR
authors.lastname: Lichtenstein
authors.forename: Michael A
authors.initials: MA
authors.lastname: Kamm
authors.forename: Prabhakar
authors.initials: P
authors.lastname: Boddu
authors.forename: Natalya
authors.initials: N
authors.lastname: Gubergrits
authors.forename: Andrew
authors.initials: A
authors.lastname: Lyne
authors.forename: Todd
authors.initials: T
authors.lastname: Butler
authors.forename: Kirstin
authors.initials: K
authors.lastname: Lees
authors.forename: Raymond E
authors.initials: RE
authors.lastname: Joseph
authors.forename: William J
authors.initials: WJ
authors.lastname: Sandborn
mesh_terms: D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage* / Q000009:adverse effects; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D019804:Mesalamine / Q000008:administration & dosage* / Q000009:adverse effects; D012074:Remission Induction; D012720:Severity of Illness Index; D012812:Sigmoidoscopy; D016896:Treatment Outcome
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D019804:Mesalamine